Figure 3 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression

Le résumé fourni par la source

Sirolimus inhibited the growth of patient-derived models of EHE. A, Cell growth inhibition curves obtained after exposure to different doses of doxorubicin or sirolimus. Data are reported as the percentage of drug-treated cells compared with control cells and represent mean ± SD of three independent experiments. B, Growth curves reporting the RTW (mean ± SEM) in control and doxorubicin- or sirolimus-treated mouse groups (nine mice/group), in which 1 indicates the tumor weight at the beginning of the treatment. The arrows indicate when drugs were administered. C, Histomorphologic evaluation of tumors obtained from untreated and drug-treated mice. D, Ki67 immunostaining of tumors obtained from untreated and drug-treated mice (top) and quantification of Ki67 index (bottom). Symbols reported in the represent counted fields. Histomorphologic analysis and Ki67 immunostaining were performed on tumors excised from mice at the end of drug treatment. Scale bar, 100 μm. Data are reported as means ± SD of three independent experiments. E, Western blot analysis of downstream mTOR pathway in untreated cells and cells treated with different sirolimus concentrations for 3 days (left) and in tumors removed from untreated and sirolimus-treated mice at the end of treatment with different drug doses (right). Cropped images of selected proteins are shown. RTW, relative tumor weight.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.